Inspire Medical Systems recently received approval from the Food and Drug Administration (FDA) for its new obstructive sleep apnea (OSA) neurostimulator therapy, named Inspire V. The company announced plans to begin a soft launch of the device by the end of 2024 with a full launch projected for 2025. This news came shortly after Inspire reported promising preliminary results for the second quarter, showcasing a 30% year-over-year revenue growth, which led to an upward revision of its full-year guidance.
Inspire Medical Systems is known for its innovative approach to treating OSA, offering a mask-free alternative to the traditional continuous positive airway pressure (CPAP) therapy. The therapy involves an implantable device that delivers pulses to shift the tongue, preventing airway blockages that disrupt sleep. This device can be activated via a remote control by patients when they go to sleep.
The new Inspire V device builds on the technology of its predecessors but includes several noteworthy improvements. One significant enhancement is the integration of the sensing function directly into the implant, which simplifies the surgical procedure by reducing the number of components that need to be implanted. This advancement is expected to decrease the average operating room time from between 60 and 90 minutes to between 45 and 60 minutes, as noted by Tim Herbert, CEO of Inspire during a May earnings call.
Additionally, Herbert highlighted in a June conference the role of Inspire V as a platform for future technological enhancements. The device is designed to support firmware upgrades, which could add new features without needing new hardware. This highlights Inspire’s commitment to innovation and its focus on enhancing efficiency and the overall patient and surgeon experience.
Analysts have reacted positively to these developments. For instance, analysts at Leerink Partners pointed out that the quicker procedure times could potentially increase capacity, allowing surgeons to treat more patients. RBC Capital Markets noted that the FDA approval came sooner than anticipated, aligning well with the launch timeline outlined by Herbert in recent investor events. Herbert assured that the transition from soft launch to full launch would be smooth, with adequate inventory levels prepared in advance.
Financially, Inspire is on an upward trajectory with a reported significant increase in revenue. In the U.S., which is its main market, revenue rose to $187.8 million, marking a year-over-year increase of 30%. The international market also saw a robust increase, with overseas income rising by 27% to $8.1 million. These strong results have prompted Inspire to raise its revenue forecast for the full year of 2024 to between $788 million and $798 million, an increase of $13 million from previous projections.
The positive financial outlook, coupled with technological advancements in the Inspire V, suggests a promising future for Inspire Medical Systems. Analysts from J.P. Morgan expressed optimism, noting that the recent financial upturn might indicate a resurgence to a consistent pattern of exceeding expectations and raised forecasts, which is vital for rebuilding investor confidence after a less stellar start to 2024.
#Inspire #wins #FDA #approval #obstructive #sleep #apnea #neurostimulator #therapy
